Enanta Pharmaceuticals will present pre‑clinical data on its STAT6 inhibitor EPS‑3903 at the IMMUNOLOGY2026 conference in Boston, scheduled for April 15‑19, 2026. The company will showcase the data in four posters, highlighting the progress of its oral small‑molecule candidate aimed at treating atopic dermatitis and other type‑2 immune disorders.
The presentation follows Enanta’s recent expansion of its immunology pipeline, which now includes programs for chronic spontaneous urticaria, atopic dermatitis, and mast cell–mediated disorders. EPS‑3903 targets IL‑4/IL‑13 signaling—a pathway also targeted by Dupixent—offering an oral alternative to injectable biologics.
Enanta plans to file an IND for EPS‑3903 in the second half of 2026, positioning the candidate for early‑phase clinical development. The pre‑clinical data demonstrate Dupixent‑like activity in animal models, supporting the therapeutic potential for atopic dermatitis and other type‑2 immune diseases.
The company views the presentation as a key milestone in its strategy to diversify beyond its RSV program and build a platform for oral immunology therapeutics. By showcasing the data, Enanta aims to attract investors and potential partners, strengthening its pipeline and accelerating progress toward clinical trials.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.